• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Direct determination of hepatic extraction of verapamil in cardiac patients.

作者信息

Woodcock B G, Schulz W, Kober G, Rietbrock N

出版信息

Clin Pharmacol Ther. 1981 Jul;30(1):52-6. doi: 10.1038/clpt.1981.126.

DOI:10.1038/clpt.1981.126
PMID:7237898
Abstract

Hepatic extraction of verapamil was determined directly in cardiac patients undergoing diagnostic catheterization and receiving 10 mg verapamil intravenously or intra-arterially. The extraction curves of verapamil concentrations in blood from the ascending aorta and hepatic vein were similar to those reported after single intravenous doses of indocyanine green. The rectilinear fall in concentration lasted 10 to 15 min. Mean hepatic extraction of verapamil in four patients who received intravenous doses was 0.86 (range 0.84 to 0.89) and in four who received intra-arterial doses was 0.87 (range 0.83 to 0.89). These estimates are the same as those for hepatic first-pass extraction determined by indirect methods based on areas under plasma concentration-time curves and requiring calculation of apparent hepatic blood flow. The results were considered to be proof that the first-pass effect of verapamil after oral doses is attributable mainly, if not entirely, to hepatic elimination.

摘要

相似文献

1
Direct determination of hepatic extraction of verapamil in cardiac patients.
Clin Pharmacol Ther. 1981 Jul;30(1):52-6. doi: 10.1038/clpt.1981.126.
2
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.利福平对维拉帕米肝前代谢和肝脏代谢的差异诱导作用。
Hepatology. 1996 Oct;24(4):796-801. doi: 10.1002/hep.510240407.
3
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.使用稳定同位素标记的维拉帕米同时测定 D,L-维拉帕米的静脉和口服药代动力学参数。
Eur J Clin Pharmacol. 1981 Jan;19(2):133-7. doi: 10.1007/BF00568400.
4
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54.
5
Verapamil pharmacokinetics and liver function in patients with cirrhosis.
Int J Clin Pharmacol Res. 1988;8(2):123-6.
6
Effect of cimetidine on verapamil disposition.
Clin Pharmacol Ther. 1985 Jun;37(6):654-7. doi: 10.1038/clpt.1985.106.
7
The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.维拉帕米和硝苯地平对乙肝表面抗原阳性肝硬化腹水患者肝脏吲哚菁绿清除率的影响。
Clin Pharmacol Ther. 1988 Oct;44(4):453-7. doi: 10.1038/clpt.1988.179.
8
Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
Clin Pharmacol Ther. 1981 Jan;29(1):27-34. doi: 10.1038/clpt.1981.5.
9
[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
Gastroenterol J. 1991;51(1):33-6.
10
Physiological disposition of verapamil in man.维拉帕米在人体中的生理分布。
Cardiovasc Res. 1976 Sep;10(5):605-12. doi: 10.1093/cvr/10.5.605.

引用本文的文献

1
Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.维拉帕米在心房颤动患者中的临床药代动力学
Eur J Clin Pharmacol. 1982;23(1):49-57. doi: 10.1007/BF01061377.
2
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.静脉注射后(+)-、(-)-和(±)-维拉帕米的药代动力学
Br J Clin Pharmacol. 1984 Apr;17(4):453-8. doi: 10.1111/j.1365-2125.1984.tb02371.x.
3
Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
慢性给药期间高清除率药物首过消除的个体间和个体内差异。氘代维拉帕米的研究。
Eur J Clin Pharmacol. 1984;26(1):47-53. doi: 10.1007/BF00546708.
4
Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.高清除率药物的立体选择性首过代谢:用稳定同位素技术研究L-维拉帕米和D-维拉帕米的生物利用度
Br J Clin Pharmacol. 1984 Nov;18(5):733-40. doi: 10.1111/j.1365-2125.1984.tb02536.x.
5
Clinical pharmacokinetics of verapamil.维拉帕米的临床药代动力学
Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002.
6
First-pass elimination. Basic concepts and clinical consequences.首过消除。基本概念及临床后果。
Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.
7
Verapamil pharmacokinetics and apparent hepatic and renal blood flow.维拉帕米的药代动力学及表观肝血流量和肾血流量
Br J Clin Pharmacol. 1985 Aug;20(2):101-6. doi: 10.1111/j.1365-2125.1985.tb05038.x.
8
Effect of a high protein meal on the bioavailability of verapamil.高蛋白餐对维拉帕米生物利用度的影响。
Br J Clin Pharmacol. 1986 Mar;21(3):337-8. doi: 10.1111/j.1365-2125.1986.tb05202.x.
9
Pharmacokinetics of conventional and slow-release verapamil.常规与缓释维拉帕米的药代动力学
Br J Clin Pharmacol. 1986;21 Suppl 2(Suppl 2):149S-153S. doi: 10.1111/j.1365-2125.1986.tb02864.x.
10
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.维拉帕米、硝苯地平和地尔硫䓬的临床药代动力学。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.